In short
This article discusses the use of Digoxin Immune Fab (Ovine), also known as DigiFab®, in clinical trials for heart failure treatment. While the primary focus of the trial is on Digoxin, DigiFab® is included as a potential treatment option. The study aims to evaluate the effectiveness and safety of Digoxin in combination with standard care for patients with chronic heart failure, with DigiFab® available as a potential antidote in case of Digoxin toxicity.
At a glance
- Trial Name
- Effects of Digoxin in Modern Heart Failure Treatment
- Primary Objective
- Assess effectiveness of Digoxin in functional capacity and cardiac function
- Study Design
- Crossover design, 48 weeks total (two 24-week periods)
- Inclusion Criteria
- Adults with chronic heart failure, LVEF ≤45%, NYHA class ≥ II
- Primary Endpoints
- Peak oxygen consumption, Global Work Index at 24 weeks
- Secondary Endpoints
- Composite of death, hospitalizations, and ventricular arrhythmia; quality of life; various cardiac function parameters
- Digoxin Immune Fab (Ovine) Role
- Potential antidote for Digoxin toxicity
What is DIGOXIN IMMUNE FAB (OVINE)?
DIGOXIN IMMUNE FAB (OVINE), also known by its brand name DigiFab®, is a medication used primarily as an antidote for digoxin toxicity. Digoxin is a heart medication used to treat various heart conditions, but it can be toxic if too much is taken. DIGOXIN IMMUNE FAB (OVINE) is a specialized antibody fragment derived from sheep (ovine means "relating to sheep") that can bind to digoxin in the bloodstream and neutralize its effects.
Medical Uses
The primary use of DIGOXIN IMMUNE FAB (OVINE) is as an antidote for digoxin toxicity. However, it's also being studied for potential use in heart failure treatment. In the clinical trial described, researchers are investigating the effects of digoxin in modern heart failure treatment. While the trial doesn't directly study DIGOXIN IMMUNE FAB (OVINE), it's included as an auxiliary medication, likely as a safety measure in case of digoxin toxicity.
The main conditions this medication is associated with include:
- Digoxin toxicity: This occurs when there's too much digoxin in the body, which can cause serious heart rhythm problems.
- Chronic heart failure: While not a primary treatment, it's being studied in relation to digoxin use in heart failure patients.
Administration
DIGOXIN IMMUNE FAB (OVINE) is administered through intravenous infusion. This means it's given directly into a vein through a drip. It's important to note that this medication is typically given in a hospital setting under close medical supervision.
Dosage
According to the clinical trial information, the maximum daily dose of DIGOXIN IMMUNE FAB (OVINE) is 200 mg, with a maximum total dose also of 200 mg. However, it's crucial to understand that dosing can vary based on individual patient needs and the severity of digoxin toxicity. The dosage should always be determined by a healthcare professional.
Clinical Trials
While the main focus of the described clinical trial is on digoxin in heart failure treatment, DIGOXIN IMMUNE FAB (OVINE) is included as an auxiliary medication. The trial aims to assess the effectiveness of digoxin in improving functional capacity and cardiac function when combined with standard heart failure treatments.
Key points about the trial include:
- It's a phase IV clinical trial, meaning it's studying an approved drug for new uses or in new populations.
- The trial includes patients with chronic heart failure who have reduced ejection fraction (a measure of how well the heart pumps blood).
- Participants must be at least 18 years old and have symptomatic heart failure.
- The study will measure various outcomes, including exercise capacity, heart function, and quality of life.
Safety Considerations
While DIGOXIN IMMUNE FAB (OVINE) is generally considered safe when used appropriately, there are some important safety considerations:
- Allergic reactions: As with any medication, some people may be allergic to DIGOXIN IMMUNE FAB (OVINE). The trial specifically excludes people with hypersensitivity to digoxin or other digitalis glycosides.
- Pregnancy and breastfeeding: The trial excludes pregnant or lactating women, suggesting caution in these populations.
- Kidney function: The trial excludes people with significant renal insufficiency, indicating that kidney function may affect the use of this medication.
- Heart rhythm issues: People with certain heart rhythm problems are excluded from the trial, suggesting that these conditions may affect the use of digoxin and potentially DIGOXIN IMMUNE FAB (OVINE).
It's important to note that this medication should only be used under close medical supervision. If you have any concerns or questions about DIGOXIN IMMUNE FAB (OVINE) or digoxin, always consult with your healthcare provider.